论文部分内容阅读
氨茶碱治疗支气管哮喘,已有近50年的历史,是临床解除支气管哮喘的有效药物,但因血浓度波动大,疗效不稳定。其主要原因是治疗窗狭窄。仅有5μg～20μ/ml的范围。常引起血液浓度超过20μg/ml而导致毒副作用的产生,同时给医生和病人带来不方便。为了达到稳定、延长有效血药浓度,服用方便,提高其疗效,近年来欧美各国制药公司相继研制氨茶碱缓释片,美国Key制药公司首先研制出Thco-Dur茶碱绥释片,现已有10余个产品供应市场。 1984年,中国医科大学、西南制药三厂,采用外国骨架和膜控先进缓释技术,经过近两年的努力,研制出氨茶碱缓释片,选择了
Aminophylline treatment of bronchial asthma, has nearly 50 years of history, is an effective drug to relieve bronchial asthma, but because of fluctuations in blood concentrations, the efficacy of instability. The main reason is the narrow therapeutic window. Only 5μg ~ 20μ / ml range. Often caused by the blood concentration of more than 20μg / ml and lead to toxic side effects, while bringing inconvenience to doctors and patients. In order to achieve stability, prolong the effective plasma concentration, take convenient and improve its efficacy, in recent years, pharmaceutical companies in Europe and the United States have developed aminophylline sustained-release tablets, the United States Key Pharmaceutical Company first developed Thco-Dur theophylline release tablets, is now There are more than 10 products supply market. In 1984, China Medical University, Southwest Pharmaceutical Factory 3, the use of foreign framework and membrane-controlled advanced sustained-release technology, after nearly two years of efforts, developed aminophylline sustained-release tablets, selected